Literature DB >> 28233576

Potential immunotherapy targets in recurrent cervical cancer.

Kari L Ring1, Anna V Yemelyanova2, Pamela T Soliman3, Michael M Frumovitz4, Amir A Jazaeri5.   

Abstract

OBJECTIVE: Our objective was to characterize the intra and peritumoral immune profile in recurrent cervical cancers to identify rational immunotherapy targets.
METHODS: Archival pelvic exenteration specimens were examined using a validated multiplex immuno-fluorescent panel of antibodies against cluster of differentiation 8 (CD8), cluster of differentiation 68 (CD68), forkhead box P3 (FoxP3), programmed cell death protein 1 (PD1), and programmed death-ligand 1 (PD-L1, N=28). Clinical data were abstracted from the electronic medical record.
RESULTS: Cytotoxic T cells, macrophages, and regulatory T cells were found in higher densities in peritumoral stroma (CD8+ density 497.7 vs 83.5, p<0.0001, CD68+ density 345.0 vs 196.7, p=0.04, FoxP3+ density 214.5 vs 35.6, p<0.0001). Antigen experienced T cells (PD1+) were higher in peritumoral compared to tumor tissue (median normalized fluorescence intensity 0.05 vs 0.0085, p<0.001). Although there was a higher median density of intratumoral cytotoxic T cells and macrophages compared to regulatory T cells (median density CD8+ 83.5 vs 35.6, p<0.05, median density 196.7 vs 35.6, p<0.05), the presence of macrophages correlated with the presence of regulatory T cells in tumors (r=0.58, p=0.001).
CONCLUSIONS: While cytotoxic T cells are present in tumor tissue to varying degrees, their density is lower than in peritumoral stroma, suggesting intratumoral exclusion or destruction of T cells. Higher densities of intratumoral macrophages compared to regulatory T cells suggest macrophages may be important contributors to the immunosuppressive tumor environment. Future directions for combination therapy include altering T cell trafficking and targeting tumor associated macrophages (TAMs) to enhance intratumoral activated T cell density and effect a more robust immune response.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cervical cancer; Immune checkpoint inhibitors; Immunotherapy

Mesh:

Substances:

Year:  2017        PMID: 28233576     DOI: 10.1016/j.ygyno.2017.02.027

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

1.  Silencing YKL-40 gene can inhibit inflammatory factor expression and affects the effect of THP-1 cells on endometrial cancer.

Authors:  Qin Luo; Jiangtao Fan; Lili Li
Journal:  Arch Gynecol Obstet       Date:  2021-08-21       Impact factor: 2.344

2.  Mining of prognosis-related genes in cervical squamous cell carcinoma immune microenvironment.

Authors:  Jiong Ma; Pu Cheng; Xuejun Chen; Chunxia Zhou; Wei Zheng
Journal:  PeerJ       Date:  2020-08-24       Impact factor: 2.984

3.  Systemic therapy for cervical carcinoma - current status.

Authors:  Krystyna Serkies; Jacek Jassem
Journal:  Chin J Cancer Res       Date:  2018-04       Impact factor: 5.087

4.  Standardized Uptake Value for 18F-Fluorodeoxyglucose Is a Marker of Inflammatory State and Immune Infiltrate in Cervical Cancer.

Authors:  John M Floberg; Jin Zhang; Naoshad Muhammad; Todd A DeWees; Matthew Inkman; Kevin Chen; Alexander J Lin; Ramachandran Rashmi; Kay Jayachandran; Brian T Edelson; Barry A Siegel; Farrokh Dehdashti; Perry W Grigsby; Stephanie Markovina; Julie K Schwarz
Journal:  Clin Cancer Res       Date:  2021-04-05       Impact factor: 12.531

Review 5.  The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer.

Authors:  Dimakatso Alice Senthebane; Arielle Rowe; Nicholas Ekow Thomford; Hendrina Shipanga; Daniella Munro; Mohammad A M Al Mazeedi; Hashim A M Almazyadi; Karlien Kallmeyer; Collet Dandara; Michael S Pepper; M Iqbal Parker; Kevin Dzobo
Journal:  Int J Mol Sci       Date:  2017-07-21       Impact factor: 5.923

6.  Active immunization combined with cisplatin confers enhanced therapeutic protection and prevents relapses of HPV-induced tumors at different anatomical sites.

Authors:  Bruna Felício Milazzotto Maldonado Porchia; Luana Raposo de Melo Moraes Aps; Ana Carolina Ramos Moreno; Jamile Ramos da Silva; Mariângela de Oliveira Silva; Natiely Silva Sales; Rubens Prince Dos Santos Alves; Clarissa Ribeiro Reily Rocha; Matheus Molina Silva; Karine Bitencourt Rodrigues; Tácita Borges Barros; Roberta Liberato Pagni; Patrícia da Cruz Souza; Mariana de Oliveira Diniz; Luís Carlos de Souza Ferreira
Journal:  Int J Biol Sci       Date:  2022-01-01       Impact factor: 6.580

7.  Trends in treatment during the last stages of life in end-stage gynecologic cancer patients who received active palliative chemotherapy: a comparative analysis of 10-year data in a single institution.

Authors:  Tae-Kyu Jang; Dae-Yeon Kim; Shin-Wha Lee; Jeong-Yeol Park; Dae-Shik Suh; Jong-Hyeok Kim; Yong-Man Kim; Young-Tak Kim; Joo-Hyun Nam
Journal:  BMC Palliat Care       Date:  2018-08-07       Impact factor: 3.234

8.  Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy.

Authors:  Jason Roszik; Kari L Ring; Khalida M Wani; Alexander J Lazar; Anna V Yemelyanova; Pamela T Soliman; Michael Frumovitz; Amir A Jazaeri
Journal:  Front Immunol       Date:  2018-09-19       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.